secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001356576-24-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus Q1: Qelbree sales +75% to $45.1M; SPN-830 gets FDA CRL; FY guidance reiterated
--------------------------------------------------------------------------------

- Total revenue of $143.6M; Qelbree net sales surged 75% YoY to $45.1M (IQVIA Rx +31%).
- Operating loss of $(3.2)M; adjusted operating earnings (non-GAAP) of $22.3M.
- Full-year 2024 guidance reaffirmed: total revenue $580M-$620M, adjusted op. earnings $80M-$110M.
- FDA issued Complete Response Letter for SPN-830 (apomorphine infusion) in Parkinson's; resubmission after May 2024 FDA meeting.
- SPN-820 Phase IIb >50% enrolled; topline data H1 2025. SPN-817 interim data call May 23; SPN-443 Phase I planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/0001356576-24-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657624000026/supn-20240508.htm
  HTML page:      https://secwatch.observer/filing/0001356576-24-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer